Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Seibyl

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 25, 2017
Cognition and the course of prodromal Parkinson's diseaseDaniel Weintraub, Lana M Chahine, Keith A Hawkins, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 22, 2015
Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findingsLama M Chahine, Daniel Weintraub, Keith A Hawkins, et al.
Expert Review of Neurotherapeutics|November 5, 2016
Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspectiveStuart H Isaacson, Stanley Fisher, Fiona Gupta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 6, 2014
In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654Olivier Barret, David Thomae, Adriana Tavares, et al.
Journal of Alzheimer'S Disease : JAD|January 28, 2020
Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission TomographyLeonie Beyer, Matthias Brendel, Franziska Scheiwein, et al.
The Lancet. Neurology|April 13, 2011
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic studyHenryk Barthel, Hermann-Josef Gertz, Stefan Dresel, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijaya L Reddy, Jesse M Cedarbaum, John Seibyl, et al.
Neurology|January 9, 2015
Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET studyDanna Jennings, John Seibyl, Marwan Sabbagh, et al.
Neurobiology of Disease|April 30, 2018
Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot studyHua Wang, Anzari Atik, Tessandra Stewart, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 2, 2014
Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeysOlivier Barret, Jonas Hannestad, David Alagille, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Movement Disorders : Official Journal of the Movement Disorder Society|October 25, 2017
Cognition and the course of prodromal Parkinson's diseaseDaniel Weintraub, Lana M Chahine, Keith A Hawkins, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 22, 2015
Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findingsLama M Chahine, Daniel Weintraub, Keith A Hawkins, et al.
Expert Review of Neurotherapeutics|November 5, 2016
Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspectiveStuart H Isaacson, Stanley Fisher, Fiona Gupta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 6, 2014
In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654Olivier Barret, David Thomae, Adriana Tavares, et al.
Journal of Alzheimer'S Disease : JAD|January 28, 2020
Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission TomographyLeonie Beyer, Matthias Brendel, Franziska Scheiwein, et al.
The Lancet. Neurology|April 13, 2011
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic studyHenryk Barthel, Hermann-Josef Gertz, Stefan Dresel, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijaya L Reddy, Jesse M Cedarbaum, John Seibyl, et al.
Neurology|January 9, 2015
Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET studyDanna Jennings, John Seibyl, Marwan Sabbagh, et al.
Neurobiology of Disease|April 30, 2018
Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot studyHua Wang, Anzari Atik, Tessandra Stewart, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 2, 2014
Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeysOlivier Barret, Jonas Hannestad, David Alagille, et al.
Pageof 11